Open AccessEfficacy of mometasone furoate for nasal polyps
Author(s) -
Hai-jiang Yu,
Lin Han,
Weifeng Wang,
Lin-hong Yang,
Yu-fei Nie
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000016632
Subject(s) - mometasone furoate , medicine , cochrane library , nasal polyps , medline , randomized controlled trial , adverse effect , subgroup analysis , meta analysis , quality of life (healthcare) , web of science , corticosteroid , political science , law , nursing
Background: This study aims to systematically explore the efficacy and safety of mometasone furoate (MTF) for patients with nasal polyps (NP). Methods: We will search MEDLINE, Cochrane Library, PubMed, Springer, Web of Science, Ovid, Wangfang and Chinese Biomedical Literature Database from their inception to April 30, 2019 without language restrictions. All randomized controlled trials (RCTs) of MTF for the treatment of NP will be considered for inclusion. RevMan 5.3 software will be used for data synthesis, subgroup analysis, sensitivity analysis, as well as the meta-analysis. Results: Primary outcomes include change in symptom scores (as measured by any symptom scores), and polyp size (as assessed by any Polyp size scores or tools). Secondary outcomes consist of polyp recurrence, change in nasal air flow, quality of life outcomes (as measured by any quality of life scales, such as Short Form Health Survey is a 36-item), and adverse events. Conclusion: This study will provide evidence for judging whether MTF is an effective and safe treatment for NP or not. PROSPERO registration number: PROSPERO CRD42019134037.